Anti-GBP1 monoclonal antibody
Anti-GBP1 antibody for FACS & in-vivo assay
Go to GBP1/GBP1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP2397-Ab-1/ GM-Tg-hg-MP2397-Ab-2 | Anti-Human GBP1 monoclonal antibody | Human |
GM-Tg-rg-MP2397-Ab-1/ GM-Tg-rg-MP2397-Ab-2 | Anti-Rat GBP1 monoclonal antibody | Rat |
GM-Tg-mg-MP2397-Ab-1/ GM-Tg-mg-MP2397-Ab-2 | Anti-Mouse GBP1 monoclonal antibody | Mouse |
GM-Tg-cynog-MP2397-Ab-1/ GM-Tg-cynog-MP2397-Ab-2 | Anti-Cynomolgus/ Rhesus macaque GBP1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP2397-Ab-1/ GM-Tg-felg-MP2397-Ab-2 | Anti-Feline GBP1 monoclonal antibody | Feline |
GM-Tg-cang-MP2397-Ab-1/ GM-Tg-cang-MP2397-Ab-2 | Anti-Canine GBP1 monoclonal antibody | Canine |
GM-Tg-bovg-MP2397-Ab-1/ GM-Tg-bovg-MP2397-Ab-2 | Anti-Bovine GBP1 monoclonal antibody | Bovine |
GM-Tg-equg-MP2397-Ab-1/ GM-Tg-equg-MP2397-Ab-2 | Anti-Equine GBP1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP2397-Ab-1/ GM-Tg-hg-MP2397-Ab-2; GM-Tg-rg-MP2397-Ab-1/ GM-Tg-rg-MP2397-Ab-2; GM-Tg-mg-MP2397-Ab-1/ GM-Tg-mg-MP2397-Ab-2; GM-Tg-cynog-MP2397-Ab-1/ GM-Tg-cynog-MP2397-Ab-2; GM-Tg-felg-MP2397-Ab-1/ GM-Tg-felg-MP2397-Ab-2; GM-Tg-cang-MP2397-Ab-1/ GM-Tg-cang-MP2397-Ab-2; GM-Tg-bovg-MP2397-Ab-1/ GM-Tg-bovg-MP2397-Ab-2; GM-Tg-equg-MP2397-Ab-1/ GM-Tg-equg-MP2397-Ab-2 |
Products Name | Anti-GBP1 monoclonal antibody |
Format | mab |
Target Name | GBP1 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-GBP1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species GBP1 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLV000305 | human GBP1 Lentivirus plasmid |
ORF Viral Vector | vGMLV000497 | human GBP1 Lentivirus particle |
ORF Viral Vector | pGMLV000497 | human GBP1 Lentivirus plasmid |
ORF Viral Vector | vGMLV000305 | human GBP1 Lentivirus particle |
Target information
Target ID | GM-MP2397 |
Target Name | GBP1 |
Gene ID | 2633 |
Gene Symbol and Synonyms | GBP1,hGBP1 |
Uniprot Accession | P32455 |
Uniprot Entry Name | GBP1_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000117228 |
Target Classification | N/A |
The target: GBP1, gene name: GBP1, also named as . Guanylate binding protein expression is induced by interferon. Guanylate binding proteins are characterized by their ability to specifically bind guanine nucleotides (GMP, GDP, and GTP) and are distinguished from the GTP-binding proteins by the presence of 2 binding motifs rather than 3. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.